[
  {
    "ts": null,
    "headline": "Cytokinetics Stock Scores RS Rating Jump To 83",
    "summary": "Cytokinetics stock cleared that benchmark Monday, with a jump from 78 to 83 Monday.  IBD's proprietary RS Rating identifies market leadership by showing how a stock's price movement over the last 52 weeks compares to that of other stocks on the major indexes.  Cytokinetics stock has climbed more than 5% past a 47.90 entry in a first-stage consolidation, meaning it's now out of a proper buy range.",
    "url": "https://finnhub.io/api/news?id=3b136b370509e446d144708d877294b257ef0403d054d3a50aea05af4b1d39f9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759173558,
      "headline": "Cytokinetics Stock Scores RS Rating Jump To 83",
      "id": 136934526,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "Cytokinetics stock cleared that benchmark Monday, with a jump from 78 to 83 Monday.  IBD's proprietary RS Rating identifies market leadership by showing how a stock's price movement over the last 52 weeks compares to that of other stocks on the major indexes.  Cytokinetics stock has climbed more than 5% past a 47.90 entry in a first-stage consolidation, meaning it's now out of a proper buy range.",
      "url": "https://finnhub.io/api/news?id=3b136b370509e446d144708d877294b257ef0403d054d3a50aea05af4b1d39f9"
    }
  }
]